Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) is -55.57% lower on its value in year-to-date trading and has touched a low of $1.58 and a high of $19.95 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AMLX stock was last observed hovering at around $6.22 in the last trading session, with the day’s gains setting it 0.32%.
Currently trading at $6.54, the stock is 31.87% and 78.16% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.73 million and changing 5.14% at the moment leaves the stock 39.42% off its SMA200. AMLX registered -64.04% loss for a year compared to 6-month gain of 246.03%. The firm has a 50-day simple moving average (SMA 50) of $3.5818 and a 200-day simple moving average (SMA200) of $4.73015.
The stock witnessed a 92.92% loss in the last 1 month and extending the period to 3 months gives it a 244.21%, and is 21.11% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.41% over the week and 11.78% over the month.
Amylyx Pharmaceuticals Inc (AMLX) has around 384 employees, a market worth around $445.26M and $298.76M in sales. Profit margin for the company is -55.52%. Distance from 52-week low is 315.24% and -67.22% from its 52-week high. The company has generated returns on investments over the last 12 months (-63.29%).
The EPS is expected to shrink by -623.81% this year
168.0 institutions hold shares in Amylyx Pharmaceuticals Inc (AMLX), with institutional investors hold 109.91% of the company’s shares. The shares outstanding are 67.71M, and float is at 41.21M with Short Float at 2.45%. Institutions hold 94.14% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 4.22 million shares valued at $8.03 million. The investor’s holdings represent 6.2251 of the AMLX Shares outstanding. As of 2024-06-30, the second largest holder is AQR CAPITAL MANAGEMENT LLC with 3.34 million shares valued at $6.35 million to account for 4.9237 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 2.67 million shares representing 3.9345 and valued at over $5.07 million, while GOLDMAN SACHS GROUP INC holds 3.8471 of the shares totaling 2.61 million with a market value of $4.96 million.
Amylyx Pharmaceuticals Inc (AMLX) Insider Activity
The most recent transaction is an insider sale by Klee Justin B., the company’s Co-Chief Executive Officer. SEC filings show that Klee Justin B. sold 18,589 shares of the company’s common stock on Sep 30 ’24 at a price of $3.20 per share for a total of $59429.0. Following the sale, the insider now owns 3.12 million shares.
Amylyx Pharmaceuticals Inc disclosed in a document filed with the SEC on Sep 30 ’24 that Cohen Joshua B (Co-Chief Executive Officer) sold a total of 18,589 shares of the company’s common stock. The trade occurred on Sep 30 ’24 and was made at $3.20 per share for $59414.0. Following the transaction, the insider now directly holds 3.22 million shares of the AMLX stock.
Still, SEC filings show that on Sep 30 ’24, Bedrosian Camille L (Chief Medical Officer) disposed off 11,442 shares at an average price of $3.20 for $36559.0. The insider now directly holds 143,801 shares of Amylyx Pharmaceuticals Inc (AMLX).
